New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 16, 2014
08:07 EDTTROVTrovagene announces clinical collaboratoin with Dana-Farber Cancer Institute
Trovagene announced that it has entered into a clinical collaboration with Dana-Farber Cancer Institute to investigate the utility of quantitative urine-based mutation detection and the ability to monitor tumor mutation burden and treatment response over time in metastatic melanoma patients. Under the agreement, urine samples will be collected from patients with locally advanced or metastatic melanoma known to harbor driver oncogene mutations.
News For TROV From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 27, 2014
08:14 EDTTROVPeer-reviewed journal features Trovagene's cancer monitoring technology
Trovagene announced the publication of clinical study results in a peer-reviewed journal, Cancer Discovery, featuring the Company's precision cancer monitoring technology and its ability to non-invasively determine oncogene mutation status and monitor response to BRAF inhibitor therapy in patients with histiocytic disease, a malignancy often associated with BRAF mutations. Clinical results will be presented at the 30th Annual Histiocyte Society Meeting on October 28 in Toronto, Canada.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use